Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway.
Physiol Genomics. 2023 Jan 1;55(1):16-26. doi: 10.1152/physiolgenomics.00098.2022. Epub 2022 Nov 14.
Lipoprotein subfractions currently represent a new source of cardiovascular disease (CVD) risk markers that may provide more information than conventional lipid measures. We aimed to investigate whether lipoprotein subfractions are associated with coronary atherosclerosis in patients without prior known CVD. Fasting serum samples from 60 patients with suspected coronary artery disease (CAD) were collected before coronary angiography and analyzed by nuclear magnetic resonance (NMR) spectroscopy. The severity of coronary atherosclerosis was quantified by the Gensini score (≤20.5 = nonsignificant coronary atherosclerosis, 20.6-30.0 = intermediate coronary atherosclerosis, ≥30.1 = significant CAD). Differences in lipoprotein subfractions between the three Gensini groups were assessed by two-way ANOVA, adjusted for statin use. Despite no differences in conventional lipid measures between the three Gensini groups, patients with significant CAD had higher apolipoprotein-B/apolipoprotein-A1 ratio, 30% more small and dense low-density lipoprotein 5 (LDL-5) particles, and increased levels of cholesterol, triglycerides, and phospholipids within LDL-5 compared with patients with nonsignificant coronary atherosclerosis and intermediate coronary atherosclerosis ( ≤ 0.001). In addition, the low-density lipoprotein (LDL) cholesterol/high-density lipoprotein cholesterol ratio, and triglyceride levels of LDL 4 were significantly increased in patients with significant CAD compared with patients with nonsignificant coronary atherosclerosis. In conclusion, small and dense lipoprotein subfractions were associated with coronary atherosclerosis in patients without prior CVD. Additional studies are needed to explore whether lipoprotein subfractions may represent biomarkers offering a clinically meaningful improvement in the risk prediction of CAD.
脂蛋白亚组分目前代表了心血管疾病(CVD)风险标志物的一个新来源,它们可能提供比传统脂质指标更多的信息。我们旨在研究脂蛋白亚组分是否与无已知心血管疾病(CVD)病史的患者的冠状动脉粥样硬化有关。在冠状动脉造影前采集了 60 名疑似冠心病(CAD)患者的空腹血清样本,并通过核磁共振(NMR)光谱分析进行了分析。通过 Gensini 评分(≤20.5=无显著冠状动脉粥样硬化,20.6-30.0=中等冠状动脉粥样硬化,≥30.1=显著 CAD)来量化冠状动脉粥样硬化的严重程度。通过双因素方差分析评估了三种 Gensini 组之间脂蛋白亚组分的差异,并对他汀类药物的使用进行了调整。尽管三种 Gensini 组之间的传统脂质指标没有差异,但与无显著冠状动脉粥样硬化和中等冠状动脉粥样硬化的患者相比,具有显著 CAD 的患者的载脂蛋白 B/载脂蛋白 A1 比值更高,小而密的低密度脂蛋白 5(LDL-5)颗粒多 30%,LDL-5 中的胆固醇、甘油三酯和磷脂水平升高(≤0.001)。此外,与无显著冠状动脉粥样硬化的患者相比,具有显著 CAD 的患者的 LDL 胆固醇/高密度脂蛋白胆固醇比值和 LDL-4 的甘油三酯水平显著升高。总之,小而密的脂蛋白亚组分与无先前 CVD 的患者的冠状动脉粥样硬化有关。需要进一步研究探讨脂蛋白亚组分是否可能代表提供 CAD 风险预测临床有意义改善的生物标志物。